| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA4644210
Max Phase: Preclinical
Molecular Formula: C20H31N5O4
Molecular Weight: 405.50
Molecule Type: Unknown
Associated Items:
Representations
Canonical SMILES: CC(C)(CC(=O)Nc1cncc(C(=O)O)c1N)NC(=O)CC1(CN)CCCCC1
Standard InChI: InChI=1S/C20H31N5O4/c1-19(2,25-16(27)9-20(12-21)6-4-3-5-7-20)8-15(26)24-14-11-23-10-13(17(14)22)18(28)29/h10-11H,3-9,12,21H2,1-2H3,(H2,22,23)(H,24,26)(H,25,27)(H,28,29)
Standard InChI Key: MZHYZICWBJVQDZ-UHFFFAOYSA-N
Associated Targets(Human)
T1R2/T1R3 282 Activities
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 405.50 | Molecular Weight (Monoisotopic): 405.2376 | AlogP: 1.88 | #Rotatable Bonds: 8 |
| Polar Surface Area: 160.43 | Molecular Species: ZWITTERION | HBA: 6 | HBD: 5 |
| #RO5 Violations: 0 | HBA (Lipinski): 9 | HBD (Lipinski): 7 | #RO5 Violations (Lipinski): 1 |
| CX Acidic pKa: 3.66 | CX Basic pKa: 9.85 | CX LogP: -1.73 | CX LogD: -2.35 |
| Aromatic Rings: 1 | Heavy Atoms: 29 | QED Weighted: 0.44 | Np Likeness Score: -0.40 |
References
| 1. Yamada K, Matsumoto R, Suzuki Y, Mori S, Kitajima S.. (2020) Design, synthesis and evaluation of unnatural peptides as T1R2/T1R3 PAMs., 30 (8): [PMID:32063432] [10.1016/j.bmcl.2020.127000] |
Source
Source(1):